Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies were originally identified in patients with CADM who had predominantly prolonged skin lesions without accompanying muscle weakness and were at risk of progressing to acute RP-ILD (14). Here, IFIH1 is linked to clinically amyopathic dermatomyositis.